Abstract: Cerebral palsy is the most prevalent cause of persisting motor function impairment with a frequency of about 1/500 births. In developed countries, the prevalence rose after introduction of neonatal intensive care, but in the past decade, this trend has reversed. A recent international workshop defined cerebral palsy as ''a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.'' In a majority of cases, the predominant motor abnormality is spasticity; other forms of cerebral palsy include dyskinetic (dystonia or choreoathetosis) and ataxic cerebral palsy. In preterm infants, about one-half of the cases have neuroimaging abnormalities, such as echolucency in the periventricular white matter or ventricular enlargement on cranial ultrasound. Among children born at or near term, about two-thirds have neuroimaging abnormalities, including focal infarction, brain malformations, and periventricular leukomalacia. In addition to the motor impairment, individuals with cerebral palsy may have sensory impairments, cognitive impairment, and epilepsy. Ambulation status, intelligence quotient, quality of speech, and hand function together are predictive of employment status. Mortality risk increases incrementally with increasing number of impairments, including intellectual, limb function, hearing, and vision. The care of individuals with cerebral palsy should include the provision of a primary care medical home for care coordination and support; diagnostic evaluations to identify brain abnormalities, severity of neurologic and functional abnormalities, and associated impairments; management of spasticity; and care for associated problems such as nutritional deficiencies, pain, dental care, bowel and bladder continence, and orthopedic complications. Current strategies to decrease the risk of cerebral palsy include interventions to prolong pregnancy (eg, 17a-progesterone), limiting the number of multiple gestations related to assisted reproductive technology, antenatal steroids for mothers expected to deliver prematurely, caffeine for extremely low birth weight neonates, and induced hypothermia for a subgroup of neonates diagnosed with hypoxicischemic encephalopathy.
Introduction
Among the variety of disorders that severely impair motor function in young children, cerebral palsy (CP) is the most prevalent. In birth cohorts from developed countries, the prevalence is 1-2/1000 live births. 1 The prevalence rises dramatically with decreasing gestational age at birth such that among extremely low gestational age newborns (ie, gestational age <28 wk), the prevalence is about 100/1000 of surviving infant, a 100-fold higher risk than infants born at term. As a function of all live births, the prevalence has been remarkably stable for decades, but this has not been the case among very low birth weight and very preterm infants, among whom prevalence increased after the introduction of neonatal intensive care and has begun to decrease in the past decade. 1 In addition to motor manifestations, children with CP frequently exhibit cognitive and sensory impairments, epilepsy, and nutritional deficiencies. Except in the mildest cases, CP has a substantial impact on families' well being and societal healthcare costs.
As a result of both laboratory-based and clinical research over the past several decades, a few perinatal interventions have been identified which probably are effective for lowering the risk of CP. Successes from clinical research on CP has been enhanced by efforts to increase the reliability (and thereby validity) of the diagnosis and classification of this disorder. These efforts have improved the efficiency of observational and experimental epidemiologic studies related to prevention, and also intervention trials for individuals with CP.
In this chapter, I will begin by reviewing research on the diagnosis and classification of CP, including efforts to standardize diagnostic criteria, quantify severity in terms of motor impairment, and impact on quality of life, and classify children with regard to location and type of neurologic abnormality, associated nonmotor impairments, and neuroimaging findings. I will then discuss the care of individuals, particularly children, with CP, with a primary focus on evidence from randomized trials. In concluding, I will discuss preventive interventions that appear likely to have an impact on the risk of CP or that are currently under study in clinical trials. Although some of these interventions are not applicable to obstetric care, it is likely that all will be of interest to obstetricians.
Diagnosis of CP
The diagnosis of CP is based on a clinical assessment, and not on laboratory testing or neuroimaging. A recent international working group offered the following definition for CP: ''Cerebral palsy is a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. '' 2 This definition allows for heterogeneity of clinical manifestations (''a group of y disorders'') and emphasizes that impaired movement and posture due to a disturbance in the brain is the invariant clinical manifestation. Although the underlying abnormality of the brain is presumed to be permanent and nonprogressive, there is overwhelming evidence that clinical manifestations and severity of functional impairment often change over time. Thus from a patient's perspective, the term ''permanent'' may connate an unduly pessimistic prognosis. In contrast to earlier definitions of CP, that proposed by the aforementioned international working group included an explicit criterion for the lower limit of abnormality that must be exceeded to diagnose CP, that is, ''activity limitation.'' On the other hand, this working group did not offer a readily operational approach to the ascertainment of activity limitation. The approach that appears to be most widely used is based on a standardized measure of motor function, the Gross Motor Function Classification System (GMFCS), 3 which will be discussed below in greater detail. The GMFCS has been included in several recent randomized clinical trials as part of the definition of severity, and in these trials children with mild CP without functional impairment were not considered to have the outcome of interest. The Western Australian Cerebral Palsy Register grades severity using the GMFCS, which allows for researchers to include or exclude cases without functional impairment. In an international study involving prematurely born children with CP, ''disabling,'' as opposed to ''nondisabling'' CP was ascertained with greater reliability, suggesting that the exclusion of cases without functional impairment may improve the validity of observational epidemiologic studies and randomized trials in which CP is an outcome. Conversely, clinicians should regard with caution those studies of CP in which information is lacking about the severity of CP, as assessed with a reliable measure.
In clinical practice, the diagnosis of CP is typically based on observations or parent reports of attained motor milestones, such as sitting, pulling to stand, and walking, and evaluation of posture, deep tendon reflexes, and muscle tone. Particularly among infants born prematurely, neurologic abnormalities, observed in the early months of life, may not be associated with motor impairment and may resolve during the first 1 or 2 years of life. One such abnormality, transient dystonia, was described in early studies of premature infants and refers to abnormal neurologic signs (eg, hyperextension of the trunk) that are no longer present after 1 year of age. Because the diagnosis of CP depends in part on neurologic findings that are subject to interexaminer variation, with regard to both the method used to elicit the neurologic finding and the interpretation of the finding, and because neurologic abnormalities may be transient, many clinicians avoid basing the diagnosis on a single aspect of the parent's report or the clinician's examination and typically will make a definitive diagnosis only after repeated examination(s).
Because CP occurs in only 1-2/1000 live births, prospective ascertainment of cases has been limited primarily to cohorts of high-risk infants, such as low birth weight babies, very preterm infants, and infants enrolled in clinical trials. For populationbased studies, registries of children with CP have been used, such as those established in Sweden, Western Australia, Metropolitan Atlanta, and Europe. Children listed in these registries are identified from records of human services providers and in some, studies the diagnosis is confirmed by examination of medical records or of the child. These population studies have been particularly informative about trends in prevalence over time.
In many recent studies of high-risk infants, [4] [5] [6] painstaking efforts were directed at standardizing the definition of CP used for prospective identification. With some minor differences between studies, each of these studies base the definition on a combination of delayed motor development (either observed or parentreported), deep tendon reflexes, posture, and muscle tone (Fig. 1) . For more details, the reader is directed to reference. 7 For both clinical and research purposes, CP has often been classified according to the nature of the movement disorder (spasticity, ataxia, dystonia, and athetosis) and the anatomic, or topographic distribution of the motor abnormalities. The predominant abnormality among children born prematurely is spasticity, referring to a velocity-dependent increase in muscle tone. Spasticity can be assessed clinically as the joint angle at which an increased muscle tone (resistance to stretch) is encountered. In a much smaller proportion of cases, referred to as having dyskinetic CP, the predominant abnormality is either dystonia or choreo-athetosis. Dystonia refers to hypertonia and reduced activity; choreoathetosis, to irregular, spasmodic, involuntary movements of the limbs or facial muscles. With ataxic CP there is a loss of orderly muscular coordination, so that movements are performed with abnormal force, rhythm, and accuracy.
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O'Shea A traditional classification of children with spastic CP includes spastic diplegia (bilateral spasticity with leg involvement greater than arm), spastic hemiplegia (unilateral spasticity), or quadriplegia (bilateral spasticity with arm involvement equal to or greater than leg). In a large population-based study of very low birth weight children with CP, 25% of children with spastic CP had hemiplegia, 37.5% had quadriplegia, and 37.5% had diplegia. Children with hemiplegia almost always develop independent ambulation, whereas a majority of those with quadriplegia do not. There is some evidence that the profile of risk factors differs for each of these topographic types of CP. It should be noted, however, that the interrater reliability of examiners' topographic classification is not high; thus the Surveillance for Cerebral Palsy in Europe (SCPE), a multicenter research collaboration, has proposed an alternative classification that includes unilateral spastic CP, bilateral spastic CP, dystonic CP, choreo-athetoid CP, and ataxia ( Fig. 2) . Currently no method of topographic classification has been broadly agreed upon.
More agreement has been achieved on classification of CP in terms of the functional severity. More than a decade ago, Palisano and his colleagues developed the GMFCS, which defines 5 levels of gross motor function, which have been shown to correspond to 5 distinct ''trajectories'' of motor development. 8 For example, among children younger than 2 years, those at level II can ''maintain floor sitting but may need to use their hands for support to maintain balance,'' whereas those at level IV have head control but trunk support is required for floor sitting.'' The GMFCS correlates strongly with the World Health Organization International Classification of Impairments, Disabilities and Handicap code, but is considerably less time-consuming and can be derived from medical records. The interrater reliability of the GMFCS is high, as is the stability over time. The GMFCS level of children, as reported by parents, agrees well with that assigned O'Shea by a physician; and the level self-reported by adults agrees well with that assigned by a physical therapist.
Other assessments have been developed for fine motor function, including the ABILHAND-Kids, the Bimanual Fine Motor Function (BFMF) Classification, and the Manual Ability Classification System. These assessments have not been studied as extensively as the GMFCS, but in 1 study, the BFMF correlated strongly with the GMFCS, and in another, a high level of agreement about the MACS was found between pairs of therapists. Thus a comprehensive description of an individual with CP would include both the GMFCS and a measure of upper extremity (fine motor) function.
In a large proportion of individuals with CP, the motor impairment is accompanied by secondary musculoskeletal problems, epilepsy, and disturbances of sensation, perception, cognition, communication, and behavior. 9 Among children registered in the SCPE Collaboration, 31% have severe intellectual disability, 11% have severe visual disability, and 21% have epilepsy. The likelihood of associated impairments varies according to topographic type. Less than one-half of children with leg dominant bilateral spastic CP have mental retardation, which is present in more than one-half of children with other forms of spastic CP. Severe visual impairment is present in more than one-half of children with 4 leg dominant spastic CP but only less than 10% of children with 2 leg dominant spastic CP.
Quality of life has been defined as ''an individual's perception of their position in life in the context of the culture and value systems in which they live, and in relation to their goals, expectations, standards and concerns.'' Using validated instruments which allow children to self-report on their quality of life, researchers have found that most children with CP report similar quality of life to children not affected with this disorder and that quality of life is not worse with greater levels of functional impairment. 10 In contrast, health-related quality of life, which measures life satisfaction in areas such as self-care, mobility, and communication is influenced by the severity of impairment.
Neuroimaging Classification
Until recently, neuroimaging studies of preterm infants with CP were based largely on neonatal cranial ultrasound. The most widely used classification system, derived from computed tomography but applied readily to ultrasound findings, was described by Papile et al. 11 In this approach to classification, grade 1 refers to hemorrhage limited to the subependymal germinal matrix region, grade 2 refers to hemorrhage in the cerebral ventricule(s), grade 3 refers to hemorrhage in the ventricle(s) with ventricular enlargement, and grade 4 refers to hemorrhage in the periventricular cerebrum. More recent approaches to classification, justified by extensive research, emphasize echolucency in the periventricular cerebrum and moderate-to-severe ventricular enlargement as most predictive of subsequent CP. 12 Very low birth weight infants with either of these abnormalities have a greater than 50% risk of developing CP. For more details see reference. 13 Most children who are born at term and subsequently develop CP do not undergo neuroimaging studies as neonates, but rather, after the diagnosis is suspected. Magnetic resonance imaging is recommended for children with neurologic findings suggestive of CP to determine if a brain abnormality is present. In a study of 273 children with CP who were born after 35 weeks' gestation and underwent neuroimaging, one-third of infants who underwent neuroimaging had normal studies. 14 The most frequent observed abnormality was focal infarction, which was observed in 22% of the children and 45% of those with hemiplegia. The next most common finding was brain malformation, including schizencephaly, hydrocephalus, polymicrogyria, lissenencephaly, agenesis of the corpus callosum, holoprosencephaly, septo-optic dysplasia, and cerebellar anomalies. In 12% of children, neuroimaging revealed periventricular leukomalacia, a finding often associated with prematurity. Of note is that only 5% of children had neuroimaging findings considered specific to hypoxia-ischemia. 14 
Care of the Child With CP
Initial assessments (Fig. 3 ) for children diagnosed with CP include neuroimaging if the etiology has not been established and metabolic and genetic studies if clinical history and findings on neuroimaging do not determine a specific etiology or if there are aspects of the history or physical examination that is suggestive of a metabolic or genetic etiology (including a brain malformation). In addition, testing for prothrombotic abnormalities of coagulation should be considered in individuals with hemiplegia. All children with CP should be screened for mental retardation, ophthalmologic and hearing impairment, and speech and language disorders, and nutrition and growth should be monitored. 15 The American Academy of Pediatrics has emphasized the importance of a primary care ''medical home'' for children with chronic illnesses, including CP. 8 The roles of the medical home include care coordination to minimize redundant services and assure comprehensive services, monitoring of response to treatments and impact of the child's illness on the family, interpreting findings to the family, orchestrating comanagement with specialists and specialty teams, and advocating for the patient with payers and providers such as the public schools. 8 (Beginning in 1975, a series of United States public laws has specified that all handicapped children have available to them a free appropriate education designed to meet their unique needs. The most recent of these is Public Law 108-446, the Individuals with Disabilities Education Improvement Act of 2004).
As discussed above, a large majority of children with CP have spasticity. Active management of spasticity is needed to prevent painful contractures and deformities and promote optimal function. This management generally is provided by multidisciplinary teams that include physical therapists, orthopedic surgeons, and physiatrists. Physical therapy, which is uniformly used for CP has not been subjected to randomized trials, but is widely accepted as a component of standard management. Table 1 describes the results of systematic reviews for 5 therapies used in the management of spasticity in patients with CP. Those provided by the Cochrane Collaboration can be assessed at http://www.mrw.interscience. wiley.com/cochrane. For each of these therapies, systematic reviews have provided evidence of benefit. Botulinum toxin type A for management of spasticity and casting for management of equinus deformity of the foot are probably the most widely available and used. Dorsal rhizotomy is a more invasive approach to the management of spastic diplegia and is reserved for the more difficult cases.
Other therapies to improve function in CP are listed in Table 2 . Therapies specific for hemiplegia, such as constraintinduced movement therapy (CIMT) and hand-arm bimanual intensive therapy (HABIT), have been studied in a relatively small number of individuals. With CIMT, the noninvolved upper extremity is restrained and the involved extremity is engaged in targeted practice. With HABIT, structured tasks requiring bimanual function are practiced in the context of play and functional activities. Although more study is warranted, these appear to hold promise of benefit. More
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O'Shea research on the effects of hyperbaric oxygen therapy is required, as there is considerable uncertainty about its efficiency and adverse effects, and this treatment costs approximately $400 per 90-minute session.
Prognosis
As discussed above, prognosis for independent ambulation depends in large part on the type of motor impairment. Ambulation status, intelligence quotient (IQ), quality of speech, and hand function together are predictive of employment status. For example, in a study of adults with CP, IQ Z80, and understandable speech, who were ambulatory and independent of the need for ''significant assistance,'' 90% were employed in a ''competitive job'' (ie, one that could be filled by a similarly qualified person without a disability). Mortality also is strongly associated with both the level of functional impairment as well as associated nonmotor impairments. In one study of over 2014 individuals with CP, the strongest predictor of mortality was intellectual disability. For example, among those with profound intellectual disability (ie, IQ <20), only one-half survived into adulthood; whereas among those with IQ >35, 92% survived to adulthood. More generally, mortality risk increases incrementally with increasing number of impairments, including intellectual, limb function, hearing, and vision. In a recent population-based study, the shortest life expectancy was observed among those individuals who were unable to lift their head in prone, who had a life expectancy of 20 years.
Antenatal Approaches to Prevention
To an alarming extent, CP is mistakenly attributed to acts of omission or commission by obstetricians. Among the most important lines of research during the past 2 decades is the investigation of the role of perinatal infection and inflammation in acquired brain damage in both term and preterm fetuses and newborns, 7, 24 and the role of prothrombotic factors and other causes of neonatal stroke in the pathogenesis of congenital hemiplegia. 25 Although epidemiologic studies indicate that less than 10% of CP results from intrapartum hypoxia, 3 quarters of US obstetricians report being the subject of a litigation event, most frequently related to their allegedly causing CP by not preventing or treating fetal hypoxia. 26 In a study of 46 malpractice cases, investigators concluded that ''the severity of the patient's disability, not the occurrence of an adverse event or an adverse event due to negligence, was predictive of payment to the plaintiff. '' 27 Many assumptions about the effectiveness of obstetric care for preventing CP generally are based on weak or no evidence. 26 Published checklists provide a more evidence-based approach to attribution. 28, 29 A intrapartum event as a cause of CP is more likely if significant fetal acidosis (such as pH <7.0) and neonatal encephalopathy are observed, and is more likely with spastic quadriplegia or dyskinetic CP. Although these events might be the result of intrapartum hypoxia, they might also be the result of fetal infection. Thus there is almost always considerable uncertainty as to the cause of CP, particularly among infants born at or near term.
Nonetheless, because approximately one-half of all new cases of CP arise from the group of neonates born prematurely, it is possible that interventions, which either prolong gestation or decrease the risk of preterm delivery will also decrease the risk of CP. Specific approaches to reduce the rate of preterm birth that are supported by a high level of evidence, include limiting the number of embryos transferred with in vitro fertilization, smoking cessation during pregnancy, screening for and treatment of asymptomatic bacteriuria during pregnancy, antiplatelet drugs to prevent preeclampsia, 17a-progesterone caproate, and cervical cerclage for women with previous preterm birth and short cervix (ie, <2.5 cm). 30 In addition, interventions which have been shown to prolong pregnancy include calcium channel blockers and an oxytocin antagonist (atosiban) for women with preterm labor and erythromycin for women with premature rupture of the membranes. 30 In addition to these measures, the results of a meta-analysis of 4 trials suggests that treatment of mothers expected to deliver before 36 weeks' gestation with glucocorticoids (eg, b-methasone) reduces the risk of CP. In the Australasian Collaborative Trial of Magnesium Sulphate, magnesium sulfate treatment of mothers at risk for preterm birth before 30 weeks' gestation reduced the risk of substantial gross motor dysfunction, and in a multicenter randomized trial in France a trend toward a reduction in cerebral white matter damage was observed. More information about the possible beneficial of antenatal magnesium sulfate is expected soon from the National Institutes of Health Maternal Fetal Medicine Network trial (Benefits of Antenatal Magnesium Sulfate).
Postnatal Approaches to Prevention
Most term or near-term infants who develop CP have uneventful neonatal courses. A notable exception are those who have neonatal encephalopathy. One of the presumed causes of neonatal encephalopathy is intrapartum cerebral hypoxia and ischemia, which in severe cases could result in permanent brain damage manifesting as CP. In such infants, hypothermia, either selectively applied to the head or total body, seems to decrease the risk of neurodevelopmental impairments, including CP. 5 Although this intervention appears to be effective, it is applicable to only a small proportion of children who subsequently develop CP.
In preterm infants, caffeine is the only therapy that has been shown in a multicenter trial to decrease the risk of CP. In this trial, extremely low birth weight infants were randomized to caffeine or placebo in the first days of life. Although the results might apply only to a small proportion of preterm infants, it is this subgroup that is at highest risk of CP. Postnatal steroids, given to premature infants to decrease lung inflammation and decrease the risk of bronchopulmonary dysplasia, increase the risk of CP. Thus limiting the use of this treatment can be expected to reduce the risk of CP. The goal of recently completed trial by the National Institutes of Health Neonatal Research Network was to study the effect of aggressive phototherapy for hyperbilirubinemia on neurodevelopmental
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O'Shea outcome. The results of this trial may be relevant to the prevention of CP in extremely low birth weight infants.
Summary
CP is relatively common cause of persistent motor impairment and is associated with a variety of developmental disabilities. In developed countries, approximately one-half of cases occur in prematurely born infants, and in this group the prevalence of CP seems to be decreasing over the past decade. In full term infants, the prevalence has been remarkably stable despite the advent of continuous fetal heart rate monitoring. The care of children with CP requires a multidisciplinary, comprehensive, and coordinated approach. In developed countries, the self-reported quality of life for adolescents with CP, except for severe cases, is similar to that of adolescents without CP.
Interventions that hold promise for reducing the prevalence of CP include interventions to decrease the risk of premature birth, antenatal steroids given to mothers expected to deliver prematurely, treatment of mothers who are expected to deliver before 30 weeks' gestation with magnesium sulfate, hypothermia for neonates diagnosed with hypoxic-ischemic encephalopathy, and caffeine for extremely low birth weight infants.
